Evidence mapPaperPMID 41110992Full record

ArticleJournal of microbiology and biotechnology2025

Daeyoung Lee, Young-Sil Lee, Gun-Seok Park, Juyi Park, Seung-Hyun Ko, You-Kyung Lee, Do Yeun Jeong, Yong Hyun Lee, Jihee Kang

Abstract read
In one paragraph

Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Journal of microbiology and biotechnology · 2026
    Article
  2. Journal of microbiology and biotechnology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Daeyoung LeeAtogen Co., Ltd., Daejeon, Republic of Korea.
Young-Sil LeeAtogen Co., Ltd., Daejeon, Republic of Korea.
Gun-Seok ParkAtogen Co., Ltd., Daejeon, Republic of Korea.
Juyi ParkAtogen Co., Ltd., Daejeon, Republic of Korea.
Seung-Hyun KoAtogen Co., Ltd., Daejeon, Republic of Korea.
You-Kyung LeeAtogen Co., Ltd., Daejeon, Republic of Korea.
Do Yeun JeongAtogen Co., Ltd., Daejeon, Republic of Korea.
Yong Hyun LeeAtogen Co., Ltd., Daejeon, Republic of Korea.
Jihee KangAtogen Co., Ltd., Daejeon, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Probiotics offer a promising avenue for combating muscle atrophy, which is a debilitating condition associated with muscle disuse, aging, and disease. This study investigated the anti-atrophic potential of

Indexed as

Limosilactobacillus reuteriMuscle StrengthMuscular AtrophyProbioticsAnimalsDisease Models, AnimalFatty Acids, VolatileGastrointestinal MicrobiomeImmobilizationMaleMiceMice, Inbred C57BLMuscle ProteinsMuscle, SkeletalSignal TransductionTOR Serine-Threonine KinasesFatty Acids, VolatilemTOR protein, mouseMuscle ProteinsTOR Serine-Threonine KinasesTrim63 protein, mouseTripartite Motif ProteinsUbiquitin-Protein Ligasesgut microbiotainflammationLimosilactobacillusmuscle atrophyprobioticsshort-chain fatty acids

Identifiers

PMID41110992
PMCPMC12549228

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.